Advanced NSCLC: From cytotoxic systemic chemotherapy to molecularly targeted therapy

Tien Hoang, Joan H. Schiller

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Approximately a third of non-small cell lung cancer patients present with disseminated disease at the time of diagnosis. For these patients, as well as those with recurrent disease, chemotherapy remains the mainstay of treatment. For several decades, researchers have attempted different combinations of drugs in search for the 'best' chemotherapy regimen. Despite the emergence of newer, 'third-generation' cytotoxic agents, success is still modest at best. Fortunately, new insights in tumor biology, leading to the design of molecularly targeted drugs, are opening a new era in cancer treatment. These novel agents target molecular pathways specifically found in cancer cells, thus maximizing the antitumor effect while minimizing toxicities on normal cells.

Original languageEnglish (US)
Pages (from-to)393-401
Number of pages9
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - Aug 2002


  • Advanced NSCLC
  • Antiangiogenesis
  • Chemotherapy
  • Epidermal growth factor receptor
  • Molecularly targeted therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Advanced NSCLC: From cytotoxic systemic chemotherapy to molecularly targeted therapy'. Together they form a unique fingerprint.

Cite this